Sutro Biopharma, Inc. is a clinical stage oncology company that develops site specific antibody drug conjugates and novel formats such as immunostimulatory ADCs bispecific ADCs and dual payload ADCs. The company uses its proprietary integrated cell free protein synthesis platform XpressCF® and its site specific conjugation platform XpressCF+® to design homogeneous product candidates against clinically validated targets where current standard of care is suboptimal. Its lead…
Sutro Biopharma, Inc. is a clinical stage oncology company that develops site specific antibody drug conjugates and novel formats such as immunostimulatory ADCs bispecific ADCs and dual payload ADCs. The company uses its proprietary integrated cell free protein synthesis platform XpressCF® and its site specific conjugation platform XpressCF+® to design homogeneous product candidates against clinically validated targets where current standard of care is suboptimal. Its lead product candidate STRO-004 targets tissue factor for solid tumor indications. Sutro Biopharma aims to transform patient lives by creating medicines with improved therapeutic profiles for areas of unmet need.
Sutro Biopharma generates revenue primarily through collaboration and license agreements with pharmaceutical and biotechnology partners. These agreements provide upfront payments milestone payments royalties and equity investments. To date the company has received approximately $1.016 billion in aggregate payments from collaborations including about $79 million in investments in its stock. The company may also out license or partner its wholly owned preclinical or clinical programs depending on resource and capital availability.
Sutro Biopharma occupies a niche in the oncology biotechnology sector by offering a platform that enables site specific conjugation and homogeneous antibody drug conjugates. This differentiates it from many competitors that rely on conventional conjugation methods which produce heterogeneous mixtures. Key competitors include larger biopharmaceutical companies developing ADCs such as Seattle Genetics Genmab Roche Pfizer and Merck & Co. as well as specialized biotech firms focused on ADC technology. The company’s competitive advantages stem from its XpressCF® platform which allows rapid protein production incorporation of non natural amino acids and scalable manufacturing without cell lines. These capabilities support faster discovery cycles and potential improvements in safety and efficacy compared with traditional ADC approaches.
Sutro Biopharma serves pharmaceutical and biotechnology companies that seek efficient drug discovery and manufacturing capabilities. Specific collaboration partners include Astellas Pharma Inc. Merck Sharp & Dohme Corp. Celgene Corporation a subsidiary of Bristol Myers Squibb EMD Serono operating under Merck KGaA Ipsen Vaxcyte Inc. Tasly and Blackstone. These partners engage the company for research development licensing and manufacturing support related to its XpressCF® and XpressCF+® platforms.